

# Eileanoir B Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4919273/publications.pdf>

Version: 2024-02-01

43  
papers

1,144  
citations

471371

17  
h-index

434063

31  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1383  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	134
2	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. <i>EBioMedicine</i> , 2015, 2, 1420-1429.	2.7	122
3	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2020, 19, 502-512.	4.9	122
4	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. <i>Biological Psychiatry</i> , 2018, 83, 456-465.	0.7	79
5	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018, 90, e717-e723.	1.5	65
6	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	64
7	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. <i>Neuropsychologia</i> , 2015, 79, 138-146.	0.7	56
8	An image-based model of brain volume biomarker changes in Huntington's disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 570-582.	1.7	50
9	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 595-608.	1.2	44
10	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. <i>JCI Insight</i> , 2017, 2, .	2.3	37
11	Testing a longitudinal compensation model in premanifest Huntington's disease. <i>Brain</i> , 2018, 141, 2156-2166.	3.7	33
12	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. <i>Biological Psychiatry</i> , 2021, 89, 807-816.	0.7	32
13	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 519.	1.1	31
14	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. <i>Annals of Neurology</i> , 2018, 83, 532-543.	2.8	26
15	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 143-149.	0.9	26
16	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 4260.	1.6	25
17	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. <i>Annals of Neurology</i> , 2020, 87, 751-762.	2.8	22
18	Huntington's disease: Brain imaging in Huntington's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 321-369.	0.9	20

#	ARTICLE	IF	CITATIONS
19	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 52-60.	0.8	20
20	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. <i>EBioMedicine</i> , 2021, 65, 103266.	2.7	20
21	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. <i>Neurology: Genetics</i> , 2021, 7, e617.	0.9	20
22	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , 2021, 158, 539-553.	2.1	18
23	MEG Adaptation Resolves the Spatiotemporal Characteristics of Face-Sensitive Brain Responses. <i>Journal of Neuroscience</i> , 2015, 35, 15088-15096.	1.7	15
24	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021, 11, 3481.	1.6	12
25	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102927.	1.4	10
26	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 634.	1.0	8
27	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI. <i>European Journal of Neuroscience</i> , 2019, 49, 1632-1639.	1.2	5
28	Longitudinal Structural MRI in Neurologically Healthy Adults. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1385-1399.	1.9	5
29	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 616272.	1.1	3
30	Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genes. <i>Brain</i> , 2022, 145, 3953-3967.	3.7	3
31	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. <i>Frontiers in Big Data</i> , 2021, 4, 662200.	1.8	2
32	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 910-918.	1.1	1
33	D9...An evaluation of methods for the volumetric measurement of grey matter in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A37.1-A37.	0.9	0
34	D10...Neurofilament light protein in blood predicts regional atrophy in huntington's disease. , 2018, , .		0
35	E11...Compensation in huntington's disease. , 2018, , .		0
36	F22...Robust biomarkers of huntington's disease progression: observations from the track-hd, predict-hd and image-hd studies. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	D09â€¦Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
38	Multimodal characterization of the visual network in Huntingtonâ€™s disease gene carriers. Clinical Neurophysiology, 2019, 130, 2053-2059.	0.7	0
39	Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images. Journal of Visualized Experiments, 2019, , .	0.2	0
40	9â€¦Aberrant striatal value representation in Huntingtonâ€™s disease gene carriers 25 years before onset. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, e4.1-e4.	0.9	0
41	F05â€¦Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
42	E01â€¦Modelling the trajectory of cortical atrophy in huntingtonâ€™s disease. , 2018, , .		0
43	E07â€¦Cerebrospinal fluid flow dynamics in huntingtonâ€™s disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , .		0